Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

INTRODUCTION: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA). This analysis aims to describe the efficacy and safety of baricitinib in Chinese RA patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yue, Li, Xing-Fu, Zhang, Xiao, Bao, Chun-De, Hu, Jian-Kang, Xu, Jian-Hua, Li, Xiang-Pei, Xu, Jian, He, Dong-Yi, Li, Zhi-Jun, Wang, Guo-Chun, Wu, Han-Jun, Ji, Fei, Zhan, Lu-Jing, Zerbini, Cristiano A. F., Li, Zhan-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695798/
https://www.ncbi.nlm.nih.gov/pubmed/32876903
http://dx.doi.org/10.1007/s40744-020-00231-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695798/
https://www.ncbi.nlm.nih.gov/pubmed/32876903
http://dx.doi.org/10.1007/s40744-020-00231-6

Ejemplares similares